Company news

Prelude Therapeutics Incorporated news in 2021

Prelude Therapeutics Incorporated's news releases, calls and decks from 2021, newest first.

View company

Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference

November 22, 2021

Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update

November 11, 2021

Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor

November 7, 2021

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

October 6, 2021

Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences

September 1, 2021

Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update

August 11, 2021

Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors

July 18, 2021

Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update

May 10, 2021

Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference

May 4, 2021

Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update

March 15, 2021

Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences

March 2, 2021

Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 10, 2021

Prelude Therapeutics Announces Pricing of Upsized Public Offering

January 6, 2021

Decks in 2021